• 1. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 5. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Vinylogous thioesters Vinylogous thioesters
• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Vinylogous thioesters

Recent Advances in the Study of 1,3-Dithiole-4-carboxylicacid (9CI) (CAS: 58758-32-0): A Comprehensive Research Brief

1,3-Dithiole-4-carboxylicacid (9CI) (CAS: 58758-32-0) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a versatile building block for the synthesis of bioactive molecules, particularly in the development of novel antioxidants, anti-inflammatory agents, and antimicrobial compounds. This research brief aims to synthesize the latest findings on this compound, highlighting its chemical properties, biological activities, and potential applications in drug discovery.

One of the key areas of interest in recent research has been the antioxidant properties of 1,3-Dithiole-4-carboxylicacid (9CI). A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent radical scavenging activity, outperforming traditional antioxidants like ascorbic acid in certain in vitro assays. The study attributed this activity to the compound's ability to stabilize free radicals through its sulfur-containing heterocyclic ring, suggesting its potential as a lead compound for the development of neuroprotective agents targeting oxidative stress-related diseases such as Alzheimer's and Parkinson's.

In the realm of antimicrobial research, a team at the University of Cambridge reported promising results in 2024 using 1,3-Dithiole-4-carboxylicacid (9CI) as a scaffold for designing novel antibacterial agents. Their work, published in Bioorganic & Medicinal Chemistry Letters, showed that specific modifications to the carboxylic acid moiety yielded compounds with significant activity against methicillin-resistant Staphylococcus aureus (MRSA) while maintaining low cytotoxicity against human cells. This finding opens new avenues for addressing the growing challenge of antibiotic resistance.

The compound's potential in cancer therapy has also been explored. A recent study in Cancer Research (2024) investigated 1,3-Dithiole-4-carboxylicacid (9CI) derivatives as potential HDAC (histone deacetylase) inhibitors. The researchers found that certain analogs exhibited selective cytotoxicity against various cancer cell lines, with particular efficacy in hematological malignancies. Molecular docking studies suggested that the dithiole ring system interacts favorably with the zinc-binding domain of HDAC enzymes, providing a structural basis for further optimization of these compounds as epigenetic modulators.

From a synthetic chemistry perspective, advances have been made in the production and modification of 1,3-Dithiole-4-carboxylicacid (9CI). A 2023 paper in Organic Letters described a novel, high-yield synthetic route that improves upon traditional methods, offering better scalability and purity. This development is particularly significant for pharmaceutical applications where consistent compound quality is paramount. Additionally, researchers have developed new strategies for functionalizing the dithiole ring system, expanding the structural diversity accessible for biological evaluation.

Despite these promising developments, challenges remain in the clinical translation of 1,3-Dithiole-4-carboxylicacid (9CI)-based therapeutics. Pharmacokinetic studies indicate that some derivatives suffer from poor bioavailability, prompting ongoing research into prodrug strategies and formulation approaches. Furthermore, the exact molecular mechanisms underlying the compound's diverse biological activities require further elucidation through detailed structure-activity relationship studies and target identification efforts.

Looking forward, the unique chemical architecture of 1,3-Dithiole-4-carboxylicacid (9CI) continues to inspire innovative research across multiple therapeutic areas. Its combination of synthetic accessibility, structural versatility, and intriguing biological profile positions it as a valuable scaffold in medicinal chemistry. Future directions likely include the exploration of its potential in combination therapies, the development of more potent and selective analogs, and the investigation of its applications in emerging areas such as targeted protein degradation and PROTAC technology.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)